Nafarelin

Origin and Structure

Nafarelin is a synthetic decapeptide GnRH agonist developed by Syntex in the 1980s. Like triptorelin, it was engineered from native GnRH by substituting the position-6 glycine with an unnatural D-amino acid — in nafarelin's case, D-3-(2-naphthyl)-alanine — which dramatically increases receptor affinity and resistance to enzymatic degradation. The result is a compound roughly 200-fold more potent than endogenous GnRH on a molar basis.

Nafarelin was approved by the FDA in February 1990 as Synarel, and its defining feature is the intranasal route of administration. Where most GnRH agonists are depot injections, nafarelin is delivered as a metered-dose nasal spray — a practical advantage for long courses in gynecological indications and in pediatric patients with central precocious puberty.

Mechanism of Action

The mechanism is shared with the broader GnRH agonist class: continuous receptor occupancy at pituitary gonadotrophs, initial flare of LH and FSH, then profound receptor downregulation and desensitization within 2–4 weeks, producing pharmacologically induced hypogonadism. Continuous high-dose agonism is pharmacologically opposite to the pulsatile stimulation that supports normal HPG function — a contrast with native gonadorelin.

The intranasal route matters for pharmacokinetics. Bioavailability is roughly 2–3% of the administered dose, which is why the twice-daily 200 mcg per spray dosing translates to meaningful systemic exposure. Absorption through the nasal mucosa is rapid, with peak plasma levels within 10–40 minutes.

Clinical Evidence and Indications

Nafarelin's FDA-approved indications are:

• Endometriosis. A 6-month course produces reliable suppression of menstruation and reduction in pelvic pain, dysmenorrhea, and dyspareunia. Pivotal trials in the late 1980s established efficacy comparable to danazol with a more favorable androgenic side-effect profile.
• Central precocious puberty in children. Nafarelin's intranasal delivery is particularly useful in this population, where chronic intramuscular depot injections are less desirable.

Nafarelin is also used off-label for pre-IVF pituitary suppression and occasionally for uterine fibroid management, though depot agonists and the newer GnRH antagonists (elagolix, relugolix) have taken over much of that space in the last decade.

Practical Considerations

The standard adult endometriosis regimen is one 200 mcg spray in one nostril in the morning and one spray in the other nostril in the evening, for a total daily dose of 400 mcg, for 6 months. If menstruation persists after 2 months, the dose can be doubled. Treatment is not typically repeated because of cumulative bone-density concerns.

Patient counseling includes avoiding nasal decongestants within 30 minutes of dosing — decongestant vasoconstriction can reduce absorption — and using non-hormonal contraception during therapy, because ovulation suppression is not guaranteed in early weeks. Upper respiratory infections and rhinitis can interfere with absorption.

The trade-off with the intranasal route is dosing discipline: missed doses matter more than with a monthly depot, and nasal irritation is an additional side effect absent from the injectable agonists.

Safety and Regulatory Status

Nafarelin's side-effect profile is dominated by hypoestrogenic symptoms: hot flashes (approximately 90% of women in pivotal trials), vaginal dryness, headache, mood changes, decreased libido, and decreased bone mineral density. The bone-density concern is the reason treatment is time-limited to 6 months without re-treatment, and some protocols include "add-back" low-dose estrogen-progestin therapy to mitigate hypoestrogenic symptoms while preserving therapeutic effect.

Nasal irritation, epistaxis, and rhinitis are specific to the intranasal route. Contraindications include pregnancy, breastfeeding, undiagnosed abnormal vaginal bleeding, and known hypersensitivity to GnRH agonists. Nafarelin is FDA-approved and on the WHO Essential Medicines List through the broader GnRH agonist class.

The Bottom Line

Nafarelin occupies a specific and durable niche in the GnRH agonist family — the intranasal option, chosen for endometriosis and precocious puberty when patients prefer self-administered daily dosing over depot injections. It is not a peptide used outside formal prescription contexts, and its mechanism is identical to the rest of the class. The interest for readers of this library is the illustration of how formulation and route can shape the clinical identity of a peptide as much as its amino-acid sequence.